-
1 Comment
Qianjiang Yongan Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 3.3% below its 200 day moving average.
From a valuation standpoint, the stock is 77.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.2.
Qianjiang Yongan Pharmaceutical Co., Ltd's total revenue sank by 21.9% to $281M since the same quarter in the previous year.
Its net income has dropped by 145.2% to $-9M since the same quarter in the previous year.
Finally, its free cash flow fell by 10.9% to $60M since the same quarter in the previous year.
Based on the above factors, Qianjiang Yongan Pharmaceutical Co., Ltd gets an overall score of 1/5.
| Exchange | SHE |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE100000LZ9 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | 3B |
|---|---|
| Beta | 0.41 |
| Target Price | 18.9 |
| Dividend Yield | 0.8% |
| PE Ratio | 116.2 |
Qianjiang Yongan Pharmaceutical Co., Ltd. manufactures and sells taurine in China. It produces ethylene oxide, water reducers, and health products. The company engages in scientific research and technical service, wholesale and retail trade, leasing and business services, and crop farming. Qianjiang Yongan Pharmaceutical Co., Ltd. was founded in 2001 and is based in Qianjiang, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002365.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
